Scynexis Inc Market Cap ($37.51 Million)
Market Cap & Net Worth: Scynexis Inc (SCYX)
Scynexis Inc market cap. Scynexis Inc (NASDAQ:SCYX) has a market capitalization of $37.51 Million ($37.51 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22768 globally and #5011 in its home market, demonstrating a -1.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scynexis Inc's stock price $3.77 by its total outstanding shares 9949609 (9.95 Million). Also see Scynexis Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Scynexis Inc Market Cap History (2015–2026)
Scynexis Inc market cap history from 2015 to 2026. Data shows change from $617.87 Million to $37.51 Million (-22.93% CAGR). Check Scynexis Inc (SCYX) share price today for real-time trading data and today's change.
Index Memberships
Scynexis Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #641 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2135 of 3165 |
Weight: Scynexis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scynexis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scynexis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SCYX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.31x
Scynexis Inc's market cap is 0.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $317.39 Million | $257.00K | -$29.99 Million | 1234.99x | N/A |
| 2017 | $230.83 Million | $257.00K | -$25.06 Million | 898.17x | N/A |
| 2018 | $47.93 Million | $257.00K | -$12.47 Million | 186.49x | N/A |
| 2019 | $90.54 Million | $121.00K | -$53.71 Million | 748.28x | N/A |
| 2020 | $76.11 Million | $12.05 Million | -$55.19 Million | 6.32x | N/A |
| 2021 | $60.69 Million | $13.16 Million | -$32.87 Million | 4.61x | N/A |
| 2022 | $15.52 Million | $5.09 Million | -$62.81 Million | 3.05x | N/A |
| 2023 | $22.19 Million | $140.14 Million | $67.04 Million | 0.16x | 0.33x |
| 2024 | $12.04 Million | $3.75 Million | -$21.29 Million | 3.21x | N/A |
| 2025 | $6.29 Million | $20.60 Million | -$8.61 Million | 0.31x | N/A |
Competitor Companies of SCYX by Market Capitalization
Companies near Scynexis Inc in the global market cap rankings as of November 3, 2026. Also see SCYX asset base for a full breakdown of the balance sheet.
Key companies related to Scynexis Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.59 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Scynexis Inc (2015–2026)
Market capitalization of Scynexis Inc from 2015 to today. Between 2015 and today, Scynexis Inc's market cap moved from $617.87 Million to $ 37.51 Million, with a yearly change of -22.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.51 Million | +496.14% |
| 2025 | $6.29 Million | -47.74% |
| 2024 | $12.04 Million | -45.74% |
| 2023 | $22.19 Million | +42.95% |
| 2022 | $15.52 Million | -74.43% |
| 2021 | $60.69 Million | -20.26% |
| 2020 | $76.11 Million | -15.93% |
| 2019 | $90.54 Million | +88.91% |
| 2018 | $47.93 Million | -79.24% |
| 2017 | $230.83 Million | -27.27% |
| 2016 | $317.39 Million | -48.63% |
| 2015 | $617.87 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Scynexis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.51 Million USD |
| MoneyControl | $37.51 Million USD |
| MarketWatch | $37.51 Million USD |
| marketcap.company | $37.51 Million USD |
| Reuters | $37.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the tre… Read more